Browsing by Yonsei Author : Cho, Byoung Chul

eperson profile image
Name:
Cho, Byoung Chul [조병철]
orcid http://orcid.org/0000-0002-5562-270X
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (7401747804)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 229

This table browses all dspace content
Issue DateTitleJournal Title
2021Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study JOURNAL OF THORACIC ONCOLOGY
2021Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study JOURNAL OF THORACIC ONCOLOGY
2021Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancerLUNG CANCER
2021The promise of bispecific antibodies: Clinical applications and challengesCANCER TREATMENT REVIEWS
2021Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial CLINICAL CANCER RESEARCH
2021Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma CLINICAL CANCER RESEARCH
2021Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2021Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC) CLINICAL LUNG CANCER
2021Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyLANCET ONCOLOGY
2021Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study CANCERS
2021Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors CANCERS
2021Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial JOURNAL OF THORACIC ONCOLOGY
2021Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?JOURNAL OF THORACIC ONCOLOGY
2021DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway EXPERIMENTAL AND MOLECULAR MEDICINE
2021Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung CancerJOURNAL OF CLINICAL ONCOLOGY
2021Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients SCIENTIFIC REPORTS
2020Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies JOURNAL FOR IMMUNOTHERAPY OF CANCER
2020Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck BRITISH JOURNAL OF CANCER
2020PrefaceMemo
2020Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768IMOLECULAR CANCER THERAPEUTICS
2020The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma JOURNAL OF THORACIC DISEASE
2020First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET EUROPEAN JOURNAL OF CANCER
2020Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinomaCANCER
2020Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea CANCER RESEARCH AND TREATMENT
2020A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapyANNALS OF ONCOLOGY
2020Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancerEXPERIMENTAL AND MOLECULAR MEDICINE
2020Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsNEW ENGLAND JOURNAL OF MEDICINE
2020Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study LUNG CANCER
2020Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer NEW ENGLAND JOURNAL OF MEDICINE
2020Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLCCANCER DISCOVERY
2020Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer JOURNAL FOR IMMUNOTHERAPY OF CANCER
2020Combination of PD-L1 and PVR determines sensitivity to PD-1 blockadeJCI INSIGHT
2020Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer CLINICAL CANCER RESEARCH
2020Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort JOURNAL FOR IMMUNOTHERAPY OF CANCER
2020Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialANNALS OF ONCOLOGY
2020Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer SCIENTIFIC REPORTS
2020Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 StudyJOURNAL OF CLINICAL ONCOLOGY
2020Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical TrialJAMA ONCOLOGY
2020Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response BRITISH JOURNAL OF CANCER
2020Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer BMC CANCER
2020Prognostic Implications of Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Amplification and Protein Overexpression in Hypopharyngeal and Laryngeal Squamous Cell Carcinoma BMC CANCER
2020Osimertinib Plus Savolitinib in Patients With EGFR Mutation-Positive, MET-amplified, Non-Small-Cell Lung Cancer After Progression on EGFR Tyrosine Kinase Inhibitors: Interim Results From a Multicentre, Open-Label, Phase 1b StudyLANCET ONCOLOGY
2020Real-world Use of Osimertinib in Non-Small Cell Lung Cancer: ASTRIS Study Korean Subgroup AnalysisCURRENT MEDICAL RESEARCH AND OPINION
2020Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC StudyCLINICAL LUNG CANCER
2020Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer EUROPEAN JOURNAL OF CANCER
2020Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLCNEW ENGLAND JOURNAL OF MEDICINE
2019Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 studyLANCET ONCOLOGY
2019Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the Phase 3 MYSTIC studyANNALS OF ONCOLOGY
2019Twist and Snail/Slug Expression in Oropharyngeal Squamous Cell Carcinoma in Correlation With Lymph Node MetastasisANTICANCER RESEARCH
2019Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer EMBO MOLECULAR MEDICINE

Browse

Links